- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06769048
지리적 위축이라 불리는 연령 관련 황반변성(AMD)의 뚜렷한 형태를 가진 사람들을 대상으로 다양한 용량의 BI 1584862를 테스트하기 위한 연구
JADE: 지리학적 위축 환자를 대상으로 한 2상 시험: BI 1584862의 효능과 안전성을 평가하기 위한 무작위, 이중 마스크, 위약 대조, 용량 찾기 연구
This study is open to adults aged 50 years and older with geographic atrophy that was diagnosed by imaging of the retina. The purpose of this study is to find out whether a medicine called BI 1584862 improves the eyes in people with geographic atrophy and to find the most suitable dose.
This study has 4 treatment groups. Participants are put into groups randomly, which means by chance. Initially participants can join a BI 1584862 and a placebo group; then more participants are put randomly in 2 additional BI 1584862 groups and a placebo group.
Participants are in the study for 1 year. During this time, they visit the study site 13 times. At the visits, doctors check the severity of participants' eye disease and collect information on any health problems. They take detailed pictures of the back of the eye, the retina, with imaging methods called fundus autofluorescence (FAF), near-infrared reflectance (NIR), and optical coherence tomography (OCT). They measure areas of the retina that appear healthy (bright) or start to waste away (dark, atrophy). The changes over time are then compared between the treatment groups.
연구 개요
연구 유형
등록 (실제)
단계
- 2 단계
연락처 및 위치
연구 장소
-
-
Arizona
-
Gilbert, Arizona, 미국, 85297
- Associated Retina Consultants
-
Phoenix, Arizona, 미국, 85020
- Associated Retina Consultants, Ltd.
-
Phoenix, Arizona, 미국, 85050
- Cameron Ria, LLC
-
Scottsdale, Arizona, 미국, 85255
- Retina Macula Institute of Arizona
-
-
California
-
Beverly Hills, California, 미국, 90211
- Retina-Vitreous Associates Medical Group
-
Glendale, California, 미국, 91204
- Global Research Management
-
Huntington Beach, California, 미국, 92647
- Retina Associates of Southern California
-
Modesto, California, 미국, 95356
- Retinal Consultants Medical Group, Inc
-
Mountain View, California, 미국, 94040
- Northern California Retina Vitreous Associates MedicalGroup, Inc.
-
Newport Beach, California, 미국, 92663
- Eye Research Foundation
-
Poway, California, 미국, 92064
- Retina Consultants of San Diego
-
Sacramento, California, 미국, 95825
- Retinal Consultants Medical Group
-
Walnut Creek, California, 미국, 94598
- Bay Area Retina Associates - Walnut Creek
-
-
Colorado
-
Denver, Colorado, 미국, 80222
- Retina Specialists of Colorado Research, LLC
-
-
Connecticut
-
Greenwich, Connecticut, 미국, 06830
- Coastal Eye Surgeons
-
-
Florida
-
Gainesville, Florida, 미국, 32605
- Vitreo Retinal Associates - Gainesville
-
Miami, Florida, 미국, 33143
- MedEye Associates
-
Pinellas Park, Florida, 미국, 33782
- Eye Associates of Pinellas
-
Stuart, Florida, 미국, 34994
- East Florida Eye Institute
-
Winter Haven, Florida, 미국, 33880
- Center for Retina and Macular Disease
-
-
Georgia
-
Augusta, Georgia, 미국, 30909
- Southeast Retina Center, PC
-
-
Illinois
-
Oak Park, Illinois, 미국, 60304
- Illinois Retina Associates - Oak Park
-
-
Kentucky
-
Louisville, Kentucky, 미국, 40206
- The Eye Care Institute
-
-
Maryland
-
Hagerstown, Maryland, 미국, 21740
- Cumberland Valley Retina Consultants
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02114
- Ophthalmic Consultants of Boston
-
-
Missouri
-
Columbia, Missouri, 미국, 65212
- University of Missouri Health System
-
-
New Jersey
-
Teaneck, New Jersey, 미국, 07666
- NJRetina
-
-
Oregon
-
Eugene, Oregon, 미국, 97401
- Verum Research, LLC
-
Portland, Oregon, 미국, 97221
- Retina Northwest
-
Portland, Oregon, 미국, 97225
- EyeHealth Northwest
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, 미국, 19107
- Mid Atlantic Retina - Wills Eye Hospital
-
-
South Carolina
-
Charleston, South Carolina, 미국, 29414
- Charleston Neuroscience Institute - Charleston
-
-
Tennessee
-
Nashville, Tennessee, 미국, 37203
- Tennessee Retina
-
-
Texas
-
Austin, Texas, 미국, 78750
- Austin Clinical Research, LLC
-
Beaumont, Texas, 미국, 77707
- Retina Consultants of Texas - Beaumont
-
Dallas, Texas, 미국, 75231
- Retina Foundation of the Southwest
-
Plano, Texas, 미국, 75024
- Red River Research Partners, LLC - Plano
-
San Antonio, Texas, 미국, 78240
- Retinal Consultants of San Antonio
-
Schertz, Texas, 미국, 78154
- Retina Consultants of Texas - Schertz
-
The Woodlands, Texas, 미국, 77384
- Retina Consultants of Texas-The Woodlands-67575
-
-
Virginia
-
Falls Church, Virginia, 미국, 22042
- Emerson Clinical Research Institute
-
Lynchburg, Virginia, 미국, 24502
- Piedmont Eye Center
-
-
Washington
-
Bellevue, Washington, 미국, 98004
- Pacific Northwest Retina
-
-
-
-
-
Arecibo, 푸에르토 리코, 00612
- Emanuelli Research & Development Center
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion criteria:
-
Men and women with at least 1 eye with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) determined by fundus autofluorescence (FAF). The total size of all GA lesions in the study eye (as determined by the independent central reading center (CRC)) must be ≥1.25 mm^2 and ≤12.0 mm^2:
- If multiple lesions are present in the study eye, at least 1 lesion must have an area of ≥0.5 mm^2
- At least 1 GA lesion must be at least in part within a 1500 μm radius ring centered on the fovea
- The foveal center point must not be involved in any atrophic lesion
- Lesion(s) must reside completely within the FAF image
-
Best corrected visual acuity (BCVA) score of ≥50 letters in the study eye using the early treatment diabetic retinopathy study (ETDRS) chart (approximately equivalent to ≥20/100 on the Snellen chart).
-
Hyperautofluorescence of any pattern, as assessed by the CRC, must be present in the junctional zone of GA in the study eye.
-
Age ≥50 years.
-
Men must be willing and able to use contraception (condom, abstinence) to prevent pregnancy and/or exposure of an existing embryo or fetus to the investigational product. A female participant is eligible if she is not a woman of childbearing potential.
-
Signed informed consent consistent with International Conference of Harmonization-Good Clinical Practice (ICH GCP) guidelines and local legislation
Exclusion criteria:
-
Any history of, or evidence of, exudative age-related macular degeneration (eAMD) in the study eye.
-
Previously received treatment for GA in the study eye within 4 months or 5 half-lives, prior to baseline, whichever is longer.
-
Previously received an investigational medication (oral or intravitreal) for GA within 4 months or 5 half-lives prior to baseline, whichever is longer.
-
Additional eye disease in the study eye that could compromise BCVA or significantly impact retinal morphology:
- uncontrolled glaucoma, defined as a disk-to-cup ratio >0.8 or ocular hypertension with intra ocular pressure (IOP) >24 mmHg at screening visit, or use of >2 active IOP-lowering agents in the study eye
- clinically significant diabetic retinopathy or maculopathy in the opinion of the investigator
- history of high myopia, i.e. spherical equivalent of ≥8 diopters or axial length ≥27.2 mm. Note: if subject had prior cataract or refractive surgery, spherical equivalent should be evaluated with pre-operative refraction. If axial length measurement is not available in medical records and cannot be obtained at screening visit, assessment of high myopia can be made by investigator on clinical examination.
- anterior segment and vitreous abnormalities that would preclude adequate observation with SD-OCT in the opinion of the investigator
- other ocular conditions at the discretion of the investigator that might interfere with the outcome of the trial
-
Significant disease or other medical conditions (as determined by medical history, examination, and clinical investigations at screening) that may, in the opinion of the investigator result in any of the following:
- put the participant at risk because of participation in the study
- influence the results of the study
- cause concern regarding the participant's ability to comply with the protocol requirements or complete the trial as scheduled (e.g. chronic alcohol or drug abuse or any other condition that, in the investigator's opinion, makes the participant an unreliable trial participant)
-
Known hypersensitivity to any of the ingredients used in the investigational medicinal product (IMP) formulation, or any of the medications used.
-
Active intraocular inflammation in the study eye.
-
Active infectious conjunctivitis in either eye. Further exclusion criteria apply.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 네 배로
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
위약 비교기: 위약 매칭 BI 1584862
|
Placebo-matching BI 1584862 |
|
실험적: BI 1584862 용량 1
|
BI 1584862 |
|
실험적: BI 1584862 용량 2
|
BI 1584862 |
|
실험적: BI 1584862 용량 3
|
BI 1584862 |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Slope of change from baseline in square root transformed geographic atrophy (GA) area as measured by fundus autofluorescence (FAF) over a treatment period of up to 50 weeks (expressed in mm/year) in the study eye
기간: Up to week 50.
|
mm is millimeters. |
Up to week 50.
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
약물 투여부터 52주차까지 TEAES 발생
기간: 52주차까지.
|
52주차까지.
|
|
|
연구 안구에서 체적 광간섭 단층촬영(OCT)으로 평가한 최대 50주차까지 두께가 20마이크로그램(μm) 미만인 황반 부위의 타원체 영역(EZ)의 백분율로 표시한 부분 감쇠의 기준선 변화
기간: 50주차까지.
|
50주차까지.
|
|
|
연구 안구에서 50주차(mm 단위로 표시)에 안저 자가형광(FAF)으로 측정한 제곱근 변형 지리형 위축(GA) 영역의 기준선 대비 변화
기간: 기준선과 50주차.
|
기준선과 50주차.
|
|
|
Key secondary endpoint: Change from baseline in total attenuation as a percentage of the EZ at the macular area with a thickness of 0 μm up to week 50 assessed by volumetric OCT and EZ mapping in the study eye
기간: Up to week 50.
|
EZ stands for ellipsoid zone. OCT stands for optical coherence tomography. |
Up to week 50.
|
|
Key secondary endpoint: Slope of change from baseline in square root transformed GA area as measured by OCT over a trial period of up to 50 weeks (expressed in mm/year) in the study eye
기간: Up to week 50.
|
GA stands for geographic atrophy. OCT stands for optical coherence tomography. mm is millimeters. |
Up to week 50.
|
|
Occurrence of BCVA letter loss of ≥15 from baseline in the study eye as measured by standardized ETDRS chart for at least 2 consecutive visits between baseline and up to Week 50
기간: Up to week 50.
|
ETDRS is early treatment diabetic retinopathy study. |
Up to week 50.
|
|
Change from baseline in best-corrected low luminance visual deficit (LLVD) score as measured in letters by ETDRS chart under low-luminance conditions at Week 50 in the study eye
기간: At baseline and at week 50.
|
ETDRS is early treatment diabetic retinopathy study. |
At baseline and at week 50.
|
공동 작업자 및 조사자
간행물 및 유용한 링크
유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
- 1484-0005
- U1111-1309-9115 (레지스트리 식별자: WHO International Clinical Trials Registry Platform (ICTRP))
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Once the criteria in section "Time Frame" are fulfilled, researchers can use the following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement".
Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.
IPD 공유 기간
One year after the approval has been granted by major Regulatory Authorities and after the primary manuscript has been accepted for publication, or after termination of the development program.
IPD 공유 액세스 기준
For study documents - upon signing of a 'Document Sharing Agreement'.
For study data - 1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .